{
  "id": 14947325,
  "title": "Stifel reiterates Crescent Biopharma stock rating on pipeline progress",
  "url": "https://urgent.news/2026/10/16/stifel-reiterates-crescent-biopharma-stock-rating-on-pipeline-progress",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-16T11:58:53.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/stifel-reiterates-crescent-biopharma-stock-rating-on-pipeline-progress-93CH-4953944"
  },
  "original_language": "en",
  "account": "Investing.com reports that Stifel maintains a Buy rating for Crescent Biopharma Inc (NASDAQ: CBIO) with a price target of $28.00 after receiving an update on the company's pipeline. The stock, currently trading at $12.48, shows significant upside potential despite a 16% decline over the past week. Stifel highlighted the completion of ASCEND trial's dose-escalation phase, involving over 125 patients, and the initiation of CR-001 expansion cohorts testing chemotherapy-based combinations for various solid tumor types. Crescent Biopharma anticipates dosing more than 2,000 patients across its portfolio by mid-fiscal year 2027, including patients from CR-001-treated ASCEND trials, CR-002-treated APOLLO trials, and more than 700 CR-003-treated patients through a partnership with Kelun. The company's fully-diluted enterprise value remains below $500 million. InvestingPro analysts deem the stock slightly overvalued relative to its Fair Value estimate. Crescent Biopharma recently completed a public offering raising around $143.7 million, with 9.3 million ordinary shares sold at $14.50 each. H.C. Wainwright upgraded the stock rating to Buy from Neutral, citing an attractive risk-reward profile and potential value in Crescent's antibody-drug conjugate pipeline.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Stifel reiterates Valmont Industries stock Buy rating at $678",
        "url": "https://urgent.news/2026/10/16/stifel-reiterates-valmont-industries-stock-buy-rating-at-678",
        "published": "2026-10-16T11:58:49.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}